Summary

The proposed study seeks to identify locally-produced Emu Oil as a novel adjunctive treatment modality for three serious gastrointestinal disorders: chemotherapy-induced mucositis, inflammatory bowel disease and NSAID-enteropathy. These three aims form the principal objectives of the study. Utilizing our proven animal model studies, these pre-clinical objectives will be addressed in Years 1 and 2 of the proposed study. Should our results appear promising at the end of Year 2, in Year 3 we will pursue commercial collaborations through which the animal model studies can be extended to human studies. This will entail engagement with the appropriate regulatory bodies. Finally, in Year 3, we will seek to determine the reproducibility of Emu Oil efficacy by investigating different batches of Emu Oil. Moreover, we will conduct a small pilot study in which Ostrich Oil and Rhea Oil are each subjected to pre-clinical examination.

Program

New and Emerging Animal Industries

Research Organisation

The University of Adelaide

Objective Summary

Aim 1: To identify effects of Emu Oil on Mucositis
We will utilize our proven rat model of 5-Fluorouracil-induced mucositis to conduct a full time-course of Emu Oil efficacy. This will include essential safety data. End-point analyses will include biochemical and histological indicators of intestinal inflammation and structural integrity.

Aim 2: To identify effects of Emu Oil on Inflammatory bowel disease (IBD)
We will utilize our proven rat model of dextran-sulphate sodium (DSS) induced ulcerative colitis to conduct a full time-course of Emu Oil efficacy. Analyses will be as for Aim 1.

Aim 3: To identify effects of Emu Oil on NSAID-enteropathy
We will utilize our proven rat model of indomethacin-induced enteropathy to conduct a full time-course of Emu Oil efficacy. Analyses will be as for Aim 1.

Aim 4: To compare different batches of Emu Oil for reproducible pre-clinical efficacy
We will compare 3-4 different batches of Emu Oil for therapeutic efficacy using the 3 model systems described above. Analyses will be as for Aim 1.

Aim 5: To conduct preliminary investigations into the therapeutic potential of Ostrich and Rhea Oils
We will obtain Ostrich Oil and Rhea Oil from established national and international collaborators. These oils will be tested for clinical efficacy in the 5-FU mucositis model (see Aim 1) as a proof-of-concept in the first instance.

Aim 6: If indicated, to commence development of human trials in humans afflicated by mucositis, IBD or NSAID-enteropathy